Last reviewed · How we verify
NCT05656729
Effect of a Multistrain Probiotic on Cold Symptoms in Healthy Patients with an History of Upper Airways Infection
NA trial testing DefensePlus in Cold Symptom in 50 participants. Completed in 30 July 2024.
30 July 2024
Quick facts
| Lead sponsor | Università degli Studi di Ferrara |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 22 December 2022 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 July 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- DefensePlus
- Placebo
Conditions studied
- Cold Symptom — all drugs for Cold Symptom →
Sponsor
Università degli Studi di Ferrara — full company profile →
Who can join
Adults 18 to 44, any sex, with Cold Symptom. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a double-blind randomized clinical trial which aims to evaluate the efficacy of a multi strain probiotic in human adults in controlling and improving cold symptoms and inflammatory response
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Efficacy of Probiotics for Relieving Cold Symptoms in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Lungaro L, Malfa P, Manza F, Negrelli M, et al · · 2025 · cited 2× · PMID 40362799 · DOI 10.3390/nu17091490
Verify or expand the search:
- PubMed search for NCT05656729
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Università degli Studi di Ferrara trials
Trials by the same sponsor.
- NCT07157696 — Advanced Respiratory Monitoring and Oxygen Therapy in Chronically Ill Patients With Acute Respiratory Failure · NA · not yet recruiting
- NCT06671106 — Efficacy of an Amine and Zinc Lactate - Containing Mouthrinse in the Home-based Treatment of Plaque-induced Gingivitis i · NA · recruiting
- NCT06482294 — CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma · Phase 2 · active not recruiting
- NCT06215001 — Individualized Selection of PEEP in Patients Affected by Expiratory Flow Limitation · NA · unknown
- NCT06769308 — Effect of Goal-directed Analgesia and Sedation Using EEG Derived QCON/qNOX in ICU Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05656729 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Università degli Studi di Ferrara
- Last refreshed: 6 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05656729.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing